Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes

August 31, 2009

Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).

Otamixaban inhibits the activity of Factor Xa, a key enzyme involved in the process of blood coagulation. It has already shown promising results when tested in patients undergoing elective angioplasty. In this trial, otamixaban was studied in high-risk patients with acute coronary syndromes (ACS). Otamixaban was compared with , a standard and very commonly used blood thinner for acute coronary syndromes. Heparin, however, has many limitations, including thinning the blood to an unpredictable degree and therefore needing frequent monitoring. "There is intense interest in finding a more effective, reliable, and safe replacement for heparin," said study lead Marc S. Sabatine, MD, MPH, an Investigator in the TIMI Study Group and a cardiologist at Brigham and Women's Hospital, who presented the findings today at the European Society of Cardiology meeting in Barcelona.

Sabatine, along with Professor Eugene Braunwald, Chairman of the TIMI Study Group, and colleagues studied the use of otamixaban in 3241 patients from 36 countries around the world who presented with ACS. The study (called SEPIA-ACS1 TIMI 42) was designed to identify the optimal dose of otamixaban. Patients were randomized into one of 5 doses of otamixaban or a comparator of heparin plus the intravenous platelet inhibitor eptifibatide. Researchers tracked the incidence of death, a second , additional coronary complications, and bleeding through 7 days (the primary endpoint) as well as over the following 6 months.

At the end of the study, Dr. Sabatine and colleagues found that in all of the otamixaban arms except the lowest one, the rate of death, a second heart attack, or additional coronary complications tended to be lower with otamixaban than with heparin plus eptifibatide. Specifically, patients receiving intermediate doses of otamixaban had a significant, 40% lower rate of death or ischemic complications compared with treatment with heparin plus eptifibatide. These benefits persisted through 180 days. The rates of bleeding in intermediate doses of otamixaban were similar to the rate in patients treated with heparin plus eptifibatide.

"The data show that intermediate doses of otamixaban may offer a substantial reduction in major coronary complications in patients presenting with an acute coronary syndrome, with bleeding rates comparable to current therapy," says Sabatine. "These findings will need to be tested in a large phase III trial to establish the definitive role of otamixaban in the treatment of acute coronary syndromes."

* Otamixaban is under development at sanofi-aventis, the company that sponsored the study. Dr. Sabatine has received honoraria and consulting fees from sanofi-aventis and honoraria from Bristol-Myers Squibb. Dr. Braunwald has received research support from Johnson & Johnson and honoraria and consultant fees from sanofi-aventis.

Source: European Society of Cardiology (news : web)


Rank not rated yet
Relevant PhysicsForums posts
  • Is Everyday Technology Killing Us?
    createdFeb 08, 2012
  • Exercise and weight loss
    createdFeb 08, 2012
  • Why do we have head aches? Our brains can't feel anything.
    createdFeb 07, 2012
  • "The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
    createdFeb 04, 2012
  • Oncolytic adenovirus
    createdFeb 04, 2012
  • Nutrition label stuffs and diets
    createdFeb 02, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Cognitive impairment in older adults often unrecognized in the primary care setting

A new study published in the Journal of the American Geriatrics Society reveals that brief cognitive screenings combined with offering further evaluation increased new diagnoses of cognitive impairment in older veterans two to ...

Medicine & Health / Diseases

created 1 hour ago | popularity not rated yet | comments 0

Primary care program helps obese teen girls manage weight, improve body image and behavior

Teenage girls gained less weight, improved their body image, ate less fast food, and had more family meals after participating in a 6- month program that involved weekly peer meetings, consultations with primary care providers ...

Medicine & Health / Health

created 1 hour ago | popularity not rated yet | comments 0

Botox developer rues missing out on billions

Botox developer Alan Scott says he rues the day he handed over rights to the best-selling wrinkle-smoothing drug to a US company for just $4.5 million, saying he might have become a billionaire.

Medicine & Health / Medications

created 2 hours ago | popularity not rated yet | comments 0

Young adults allowed to stay on parents' health insurance have improved access to care

Researchers from Mount Sinai School of Medicine have found that laws permitting children to stay on their parents' health insurance through age 26 result in improved access to health care compared to states without those ...

Medicine & Health / Health

created 1 hour ago | popularity not rated yet | comments 0

Cancer rate 4 times higher in children with juvenile arthritis

New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal publis ...

Medicine & Health / Diseases

created 1 hour ago | popularity not rated yet | comments 0


Rapunzel, Leonardo and the physics of the ponytail

(PhysOrg.com) -- New research provides the first mathematical understanding of the shape of a ponytail and could have implications for the textile industry, computer animation and personal care products.

Climate change causes harmful algal blooms in North Atlantic: study

Warming oceans and increases in windiness could be causing of an abundance of harmful algal blooms in the North Atlantic Ocean and North Sea, according to new research.

Hacker claims porn site users compromised

A hacker claims to have compromised the personal information of more than 350,000 users after breaking into a disused website operated by pornography provider Brazzers.

AT&T customers surprised by 'unlimited data' limit

(AP) -- Mike Trang likes to use his iPhone 4 as a GPS device, helping him get around in his job. Now and then, his younger cousins get ahold of it, and play some YouTube videos and games.

Scientists discover molecular secrets of 2,000-year-old Chinese herbal remedy

For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, ...

Integrated pest management recommendations for the southern pine beetle

The southern pine beetle, Dendroctonus frontalis Zimmermann, is a chronic insect pest within pine forests in the southeastern United States. Under favorable environmental and host conditions, it is an agg ...